Results 71 to 80 of about 1,814 (132)

Early retinal volume changes after switching to brolucizumab in refractory neovascular age-related macular degeneration. [PDF]

Front Ophthalmol (Lausanne)
Matsuki T, Akiyama K, Watanabe K, Noda T, Sasaki M.   +4 more
europepmc   +1 more source

Alternative posology for brolucizumab: a 6-week loading regimen is as effective as a 4-week regimen for the treatment of nAMD. [PDF]

BMJ Open Ophthalmol
Mulyukov Z, Olgac U, Kearns JD, Liu C, Pigeolet E, Weissgerber G.   +5 more
europepmc   +1 more source

Proactive Post-Injection Monitoring in Brolucizumab Therapy: A Study on Intraocular Inflammation and Treatment Outcomes

Clinical Ophthalmology
Manoj Soman,1,2 Apoorva Jadhav,1,2 Abhaya Balakrishnan,1,2 Jay U Sheth,3 Unnikrishnan Nair1,2 1Department of Vitreoretinal Services, Chaithanya Eye Hospital and Research Institute, Trivandrum, India; 2Department of Research, Chaithanya Innovation in ...
Soman M, Jadhav A, Balakrishnan A, Sheth JU, Nair U   +4 more
doaj  

Choroidal Changes after Intravitreal Aflibercept, Faricimab, Brolucizumab, and High-Dose Aflibercept in Treatment-Naïve Neovascular Age-Related Macular Degeneration. [PDF]

Ophthalmol Sci
Razavi S, Menna M, Fragiotta S, Van Herreweghe S, Lazzerini A, Battista M, Beretta F, Sacconi R, Querques G.   +8 more
europepmc   +1 more source

Long-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy). [PDF]

Indian J Ophthalmol
Verma L, Singh S, Talwar D, Gupta A, Khare G, Ramachandran ON, Bhanupriya, Gujral GS, Harish HS, Gupta N.   +9 more
europepmc   +1 more source

Real-World Experience with Brolucizumab in Treatment-Naïve nAMD with Low Baseline Visual Acuity: Short-Term Outcomes from a Prospective Single-Institution Study. [PDF]

Life (Basel)
Hajdari A, Uka V.
europepmc   +1 more source

Paradoxical angiogenic activation under anti-VEGF therapy: tip cell hyper-sprouting and vessel remodeling drive inefficient vascularization in multiscale tumor simulations. [PDF]

BMC Cancer
Manshadi MD, Soltani M.
europepmc   +1 more source

Intravitreal Brolucizumab for Diabetic Macular Edema: Outcomes in Treatment-Naive and Anti-VEGF-Switched Eyes over 48 Weeks. [PDF]

J Clin Med
Higashijima F, Ota Y, Jiromaru H, Tamura Y, Funatsu M, Aoki R, Mikuni M, Ohta M, Wakuta M, Hirano S, Yamauchi K, Kimura K.   +11 more
europepmc   +1 more source

Proteomic profiling reveals treatment-dependent inflammatory signatures and identifies biomarkers of refractory age-related macular degeneration. [PDF]

Front Pharmacol
Eandi CM, Borgo A, de Oliveira Figueiredo E, de Haro D, Kaufmann DE, Roduit R.   +5 more
europepmc   +1 more source

Efficacy of brolucizumab and ranibizumab in diabetic macular edema and neovascular age-related macular degeneration: insights from a case series. [PDF]

Ann Med Surg (Lond)
Hossain B, Rahmatullah S, Ahmed T.
europepmc   +1 more source